Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Bayer Schering Pharma AG' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Bayer Schering Pharma AG' found in 1 term [] and 21 definitions []
1 - 5 (of 22)     next
Result Pages : [1]  [2 3 4 5]
Searchterm 'Bayer Schering Pharma AG' was also found in the following services: 
spacer
News  (2)  Resources  (1)  
 
Bayer Schering Pharma AGMRI Resource Directory:
 - Manufacturers -
 
www.bayerscheringpharma.de/scripts/pages/en/index.php The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology and Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and computed tomography are 'world-market leaders'.

MRI Contrast Agents:
Contact Information
MAIL
Bayer Schering Pharma AG
51368 Leverkusen
GERMANY
PHONE
+49-30-46-81-2431
FAX
+49-30-46-81-8195
spacer
 
• Share the entry 'Bayer Schering Pharma AG':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'Bayer Schering Pharma AG' (25).Open this link in a new window.
 
Further Reading:
  News & More:
Drastic market changes with MRI contrast media and PET radiopharmaceuticals emerging as most promising segments
Thursday, 21 October 2004   by www.news-medical.net    
Epix Pharmaceuticals to shut down
Tuesday, 21 July 2009   by boston.bizjournals.com    
Searchterm 'Bayer Schering Pharma AG' was also found in the following services: 
spacer
Radiology  (6) Open this link in a new windowUltrasound  (8) Open this link in a new window
Magnevist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Magnevist® is a paramagnetic ionic contrast agent for use in magnetic resonance imaging. Contrast enhanced MRI with Magnevist® allows additional diagnostic information of tumors, inflammation and vascular lesions and the determination or differentiation of such lesions.
The contrast enhancing effect is produced by the di-N-methylglucamine salt of gadopentetate (Gd-DTPA), the gadolinium complex of diethylenetriamine pentaacetic acid. Magnevist® has the strongest effect on T1 weighted images, by increasing T1 signal intensity in tissues where Magnevist® has accumulated.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Ionic Intravenous Contrast Agents and Gadopentetate Dimeglumine.
Drug Information and Specification
CENTRAL MOIETY
Gd3+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.4, r2=3.8, B0=1.0T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
1960 mosm/kgH2O
CONCENTRATION
0.5 mol/L
DOSAGE
0.1-0.3 mmol/kg / 0.2-0.6 mL/kg
PREPARATION
Finished product
INDICATION
Neuro/whole body
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vials of 5, 10, 15, 20 and 100 mL bulk package
Pre-filled syringes of 10, 15 and 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA, Canada
Magnevist®
for sale
Asia
Magnevist®
for sale
EU
Magnevist®
suspended
Turkey
Magnevist®, Magnograf
for sale
Australia
Magnevist®
for sale
spacer

• View the DATABASE results for 'Magnevist®' (7).Open this link in a new window

 
Further Reading:
  Basics:
Magnevist Prescription Drug Discount Sources
   by www.institutedc.org    
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
MAGNEVIST ® (brand of gadopentetate dimeglumine) Injection - WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
May 2009   by berlex.bayerhealthcare.com    
Magnevist Package Insert
2000
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
Gadolinium-containing contrast agents: removal of Omniscan and iv Magnevist, restrictions to the use of other linear agents
Friday, 5 January 2018   by www.gov.uk    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
October 2004   by www.findarticles.com    
MRI Resources 
Patient Information - MRCP - Health - Breast Implant - Journals - Spectroscopy pool
 
Bayer HealthCare PharmaceuticalsMRI Resource Directory:
 - Manufacturers -
 
berlex.bayerhealthcare.com In June 2006 Bayer AG has bought the majority of shares of Schering AG. As a result of this take-over Schering AG has been renamed in December 2006 in Bayer Schering Pharma AG. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group.
Berlex Laboratories (USA) and Berlex Canada Inc., former affiliates of Schering AG, have been integrated into Bayer HealthCare and operate as a specialty pharmaceuticals business that also sells MRI contrast agents, under the name Bayer HealthCare Pharmaceuticals, which is a subsidiary of Bayer Schering Pharma AG.
Contact Information
MAIL
Bayer HealthCare Pharmaceuticals
Headquarters?
PHONE
+1-888-842-2937
spacer

• View the DATABASE results for 'Bayer HealthCare Pharmaceuticals' (8).Open this link in a new window


• View the NEWS results for 'Bayer HealthCare Pharmaceuticals' (2).Open this link in a new window.
 
Further Reading:
  News & More:
New data presented at RSNA on use of Bayer's Gadavist® (gadobutrol) injection in children less than 2 years of age
Wednesday, 3 December 2014   by www.prnewswire.com    
Searchterm 'Bayer Schering Pharma AG' was also found in the following services: 
spacer
News  (2)  Resources  (1)  
 
Gadovist®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Gadovist® is an extracellular, neutral macrocyclic (gadolinium (Gd) complex) MRI contrast agents for central nervous system indications, particularly suited for studies in which high doses are required or advantageous. Gadovist® (also Gadograf) was available in two concentrations, currently only Gadovist® 1.0 is marketed.
The product was approved in Switzerland in 1999 and in Germany in 2000. Gadovist® 1.0 is in USA currently in the drug development and approval process, particularly for magnetic resonance angiography.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Paramagnetic Contrast Agents and Gadobutrol.
Drug Information and Specification
NAME OF COMPOUND
Gadobutrol, Gd-BT-DO3A
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, Predominantly positive enhancement
r1=3.6, B0=1.0 T
PHARMACOKINETIC
Intravascular, extracellular, renal excretion
OSMOLALITY
557 and 1603 mosm/kgH2O
CONCENTRATION
1 mol/L
DOSAGE
0.1mmol/kg
PREPARATION
Finished product
INDICATION
Central nervous system / whole body
DEVELOPMENT STAGE
For sale / submit for approval
DISTRIBUTOR
See below
PRESENTATION
Vials of 15, 30 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
Gadovist®
Submit for approval
Japan
Gadovist®
EU
Gadovist®
for sale
Australia
Gadovist®
for sale
spacer

• View the DATABASE results for 'Gadovist®' (5).Open this link in a new window

 
Further Reading:
  Basics:
Important Drug Warning for Gadolinium-Based Contrast Agents
Wednesday, 12 September 2007   by www.ismrm.org    
Gadograf, Gadovist
Friday, 13 April 2007   by www.ema.europa.eu    
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings
Tuesday, 19 December 2017   by www.fda.gov    
FDA approves Bayer's Gadavist® (gadobutrol) injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age
Monday, 5 January 2015   by www.prnewswire.com    
New data presented at RSNA on use of Bayer's Gadavist® (gadobutrol) injection in children less than 2 years of age
Wednesday, 3 December 2014   by www.prnewswire.com    
Searchterm 'Bayer Schering Pharma AG' was also found in the following services: 
spacer
Radiology  (6) Open this link in a new windowUltrasound  (8) Open this link in a new window
Magnevist® EnteralInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Magnevist® enteral (Gadopentetate) is a Gd-DTPA solution for use as a gastrointestinal contrast agent to visualize the bowel in MRI scans.

See also Positive Oral Contrast Agents and Gadopentetate Gastrointestinal.
Drug Information and Specification
CENTRAL MOIETY
Gd3+
CONTRAST EFFECT
T1, Predominantly positive enhancement
Paramagnetic
PHARMACOKINETIC
Gastrointestinal
CONCENTRATION
0.001 mol/L
DOSAGE
100 ml oral
PREPARATION
Finished product
INDICATION
Bowel marking
DEVELOPMENT STAGE
For sale
DISTRIBUTOR
See below
PRESENTATION
Vial of 100 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
USA
Magnevist® enteral
for sale
EU
Magnevist® enteral
for sale
spacer

• View the DATABASE results for 'Magnevist® Enteral' (3).Open this link in a new window

MRI Resources 
MRI Centers - Artifacts - Pacemaker - Safety Products - Functional MRI - Services and Supplies
 
     1 - 5 (of 22)     next
Result Pages : [1]  [2 3 4 5]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



How AI will impact MRI :
only diagnostics 
saving time 
reducing cost 
makes planning obsolete 
reduce human knowledge 
not at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]